27.24
-1.00 (-3.54%)
| Previous Close | 28.24 |
| Open | 28.00 |
| Volume | 386,025 |
| Avg. Volume (3M) | 582,435 |
| Market Cap | 1,021,168,960 |
| Price / Earnings (Forward) | 46.73 |
| Price / Sales | 4.54 |
| Price / Book | 82.92 |
| 52 Weeks Range | |
| Earnings Date | 9 Nov 2026 |
| Profit Margin | -10.19% |
| Operating Margin (TTM) | -23.48% |
| Diluted EPS (TTM) | -0.610 |
| Quarterly Revenue Growth (YOY) | 38.30% |
| Total Debt/Equity (MRQ) | 410.02% |
| Current Ratio (MRQ) | 0.910 |
| Operating Cash Flow (TTM) | 2.09 M |
| Levered Free Cash Flow (TTM) | -26.88 M |
| Return on Assets (TTM) | 0.90% |
| Return on Equity (TTM) | -37.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Harrow, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | -5.0 |
| AI Insight | NA |
| Weighted Average | -0.71 |
Select this tab to load the latest available analysis.
|
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 15.07% |
| % Held by Institutions | 57.11% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |